Medtronic (NYSE:MDT) announced today that it received FDA approval for its DiamondTemp ablation (DTA) system for treating Afib.
Fridley, Minn.-based Medtronic’s DiamondTemp ablation system treats patients with recurrent, symptomatic paroxysmal Afib who have been unresponsive to drug therapy. The medtech giant touts DiamondTemp as the first FDA-approved, temperature-controlled, irrigated radiofrequency ablation system with diamonds currently available to deliver ablations.
DiamondTemp delivers radiofrequency energy (heat) during ablations with real-time feedback on physical parameters to guide physicians as the lesion is being produced.
Embedded with industrial-grade diamonds with 200-400 times greater thermal conductivity compared to materials used in standard radiofrequency ablation catheters, the DiamondTemp ablation catheter offers thermal conductivity to enable a low irrigation flow-rate, as well as real-time measurements of tissue temperature, according to a news release.
The system is also designed to record high-resolution electrogram (EGM) signals that can be used as a physical indicator of lesion formation and for guidance with ablation location, Medtronic said.
“With the FDA approval of the DiamondTemp system, Medtronic continues to drive clinical research and innovation to find differentiated solutions that meet the needs of patients and clinicians, who are on the front lines of patient care,” Medtronic president of cardiac ablation solutions Rebecca Seidel said in the release. “DTA is the only FDA-approved, temperature-controlled, irrigated RF ablation system on the market today.
“The addition of DTA will enable Medtronic to continue to expand our portfolio in new ways with cutting edge arrythmia solutions to help patients control their AF.”
Original Article: https://www.massdevice.com/medtronic-wins-fda-approval-for-diamondtemp-ablation-system/
